Novel Exatecan-Amide Linker-Payload Designs for Stable Antibody-Drug Conjugates

Ryan V. Quiroz published a dataset on figshare in 2026 describing a structure-activity relationship (SAR) campaign for novel camptothecin-derived linker-payloads. The dataset, 2.6 KB in size, likely contains design parameters and performance metrics for antibody-drug conjugates (ADCs). The most promising candidates reportedly achieved low aggregation (<5%), stability, and significant tumor regression in vivo.

Use Cases

• Optimizing linker-payload stability based on the described Ala-Ala protease-cleavable peptide linker.
• Evaluating aggregation propensity in ADC formulations based on the reported <5% aggregation metric.
• Designing novel camptothecin-derived payloads based on the described butanediol Exatecan-amide structure.
• Assessing in vivo efficacy of ADC candidates based on the reported tumor regression results.

Strengths

• Dataset is small (2.6 KB), facilitating quick download and inspection.
• Description provides specific performance targets, such as low aggregation (<5%) and no DAR loss in vitro/vivo.
• The work outlines a complete SAR campaign for a modular linker platform.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Description metadata is limited; actual data quality requires manual inspection after download.

Provenance

Source

Ryan V. Quiroz via figshare

Collection Method

Likely contains results from a synthetic and medicinal chemistry SAR campaign.

Freshness

Last updated 2026-04-30 10:04:40; freshness should be verified.